MedTrace Logo

Weekly Carboplatin and Taxotere in Platinum Sensitive Relapsed Ovarian or Tubal or Primary Peritoneal Cancers

NCT00247988 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2007-04-24

No results posted yet for this study

Summary

Weekly carboplatin and taxotere will be tolerable and effective as second line treatment of platinum-sensitive ( \>6 month treatment free interval) relapsed ovarian cancer

Primary efficacy parameter will be response rate (CR and PR) according to RECIST criteria.

Secondary endpoints will be duration of response, progression free survival and overall survival. Toxicity will also be evaluated.

Conditions

  • Platinum Sensitive Relapsed Ovarian Cancer

Interventions

DRUG

Weekly Taxotere with weekly carboplatin

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • University of Saskatchewan

    lead OTHER

Principal Investigators

  • mohammed salim, MD · Saskatoon Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Completion
2007-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00247988 on ClinicalTrials.gov